Clearside Biomedical completes Series A financing

With an investment from the GRA Venture Fund, LLC, Clearside Biomedical has completed its Series A financing.  The company, which got its start through GRA VentureLab grants, is developing microinjection technology that uses hollow needles to target therapeutics precisely within the eye.  Based on a collaboration of researchers at Georgia Tech and Emory, the technology has the potential to provide an improved method for treating diseases that affect the back of the eye, including age-related macular degeneration.  North Carolina-based Hatteras Discovery Fund also invested $4 million in Clearside.

Read more here about the technology, its development and potential  or visit Clearside Biomedical’s website.